[go: up one dir, main page]

UY32704A - Compuestos de 2,3-dihidro-1h-indeno - Google Patents

Compuestos de 2,3-dihidro-1h-indeno

Info

Publication number
UY32704A
UY32704A UY0001032704A UY32704A UY32704A UY 32704 A UY32704 A UY 32704A UY 0001032704 A UY0001032704 A UY 0001032704A UY 32704 A UY32704 A UY 32704A UY 32704 A UY32704 A UY 32704A
Authority
UY
Uruguay
Prior art keywords
compounds
dihidro
indeno
dihydro
manufacturing
Prior art date
Application number
UY0001032704A
Other languages
English (en)
Inventor
Brian Aquila
Hennessy Edward
Alexander Hird
Oza Vibha
Jamal Carlos Saeh
Sha Li
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY32704A publication Critical patent/UY32704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente compuestos de 2,3-dihidro-1H-indeno, métodos para la fabricación de los compuestos y composiciones farmacéuticas que contienen los compuestos. Los compuestos descritos inhiben las proteínas IAP y pueden utilizarse para tratar varios cánceres.
UY0001032704A 2009-06-12 2010-06-11 Compuestos de 2,3-dihidro-1h-indeno UY32704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659409P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
UY32704A true UY32704A (es) 2011-01-31

Family

ID=42630911

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032704A UY32704A (es) 2009-06-12 2010-06-11 Compuestos de 2,3-dihidro-1h-indeno

Country Status (11)

Country Link
US (1) US20100317593A1 (es)
EP (1) EP2440549A1 (es)
JP (1) JP2012529482A (es)
KR (1) KR20120046162A (es)
CN (1) CN102459238A (es)
AR (1) AR077080A1 (es)
AU (1) AU2010258437A1 (es)
CA (1) CA2765150A1 (es)
TW (1) TW201103536A (es)
UY (1) UY32704A (es)
WO (1) WO2010142994A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3831811A4 (en) 2018-07-31 2022-04-20 Fimecs, Inc. HETEROCYCLIC COMPOUND
WO2020046941A1 (en) * 2018-08-28 2020-03-05 Arbutus Biopharma Corporation Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same
WO2020109328A1 (en) 2018-11-26 2020-06-04 Debiopharm International S.A. Combination treatment of hiv infections
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
WO2020110056A1 (en) * 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
WO2020148447A1 (en) 2019-01-17 2020-07-23 Debiopharm International S.A. Combination product for the treatment of cancer
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
PH12022550721A1 (en) 2019-09-25 2024-05-13 Debiopharm Int Sa Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
JP7659553B2 (ja) * 2019-11-08 2025-04-09 サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
AU2023275703A1 (en) 2022-05-23 2024-11-21 Inhibrx Biosciences, Inc. Dr5 agonist and iap antagonist combination therapy
WO2025090605A1 (en) 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
WO2025217052A1 (en) 2024-04-08 2025-10-16 University Of Houston System Combinations of an iap inhibtor, a tyrosine kinase inhibitor and an activator of the tnf a induced cell death pathway and their use in the treatment of proliferative diseases or disorders such as cancer or pulmonary diseases

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396964B1 (en) * 1989-04-28 1995-09-06 SCLAVO S.p.A. Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US6187557B1 (en) * 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
US6162965A (en) * 1997-06-02 2000-12-19 Novartis Ag Plant transformation methods
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6162913A (en) * 1998-07-15 2000-12-19 Bristol-Myers Squibb Co. Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20080199439A1 (en) * 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
AU2005218555B2 (en) * 2004-03-01 2008-01-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
WO2005092326A1 (en) * 2004-03-22 2005-10-06 The Regents Of The University Of Michigan Small molecule antagonists of xiap family proteins
WO2006014361A1 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
US20100190688A1 (en) * 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
JP5230865B2 (ja) * 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
DK1851200T3 (da) * 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
CA2607940C (en) * 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
CA2610396A1 (en) * 2005-06-08 2006-12-14 Novartis Ag Organic compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) * 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN101340947B (zh) * 2005-12-20 2012-09-05 诺瓦提斯公司 Iap-抑制剂和紫杉烷7的组合
TWI543988B (zh) * 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US20090043099A1 (en) * 2006-03-17 2009-02-12 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
MY159563A (en) * 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
EP2049563B1 (en) * 2006-07-24 2014-03-12 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
JP5190062B2 (ja) * 2006-10-12 2013-04-24 ノバルティス アーゲー Ｉａｐ阻害剤としてのピロリジン誘導体
KR20090087094A (ko) * 2006-11-28 2009-08-14 노파르티스 아게 Ｉａｐ 억제제 및 ｆｌｔ3 억제제의 조합물
MX2009005551A (es) * 2006-11-28 2009-06-08 Novartis Ag Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
JP2010512322A (ja) * 2006-12-07 2010-04-22 ノバルティス アーゲー 有機化合物
US8048886B2 (en) * 2006-12-07 2011-11-01 Novartis Ag Substituted pyrazine-3-one-derivatives as IAP inhibitors
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2310402A1 (en) * 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
US20110177060A1 (en) * 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap

Also Published As

Publication number Publication date
TW201103536A (en) 2011-02-01
KR20120046162A (ko) 2012-05-09
WO2010142994A1 (en) 2010-12-16
CN102459238A (zh) 2012-05-16
CA2765150A1 (en) 2010-12-16
US20100317593A1 (en) 2010-12-16
EP2440549A1 (en) 2012-04-18
AR077080A1 (es) 2011-07-27
JP2012529482A (ja) 2012-11-22
AU2010258437A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
ECSP10010129A (es) Inhibidores de quinasas símil polo
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UA114087C2 (xx) Похідні піридину
UY35467A (es) Compuestos orgánicos
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
EA201170772A1 (ru) Органические соединения
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
ECSP10010722A (es) Compuestos orgánicos
SV2011003855A (es) Heteroarilos sustituidos
CR20140275A (es) Triazolopiridinas sustituidas
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
EA201270254A1 (ru) Производные 5-фторпиримидинона
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP13012519A (es) Compuestos sustituidos de benzamida
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190206